Skip to main content
Home
  • About Us
    • About Us
    • Mission & Values
    • Leadership
    • News
    • Careers
    • Partnerships
    • Support
    • Achievements
  • For Researchers
    • Clinical Trials
      • Allergy & Asthma
      • Autoimmune Disease
      • Transplantation
      • Type 1 Diabetes
    • Core Facilities
    • Lab Protocols
      • ITN Protocols
      • T1D Preclinical Consortium
    • Policies
      • Publications Policy
    • Proposals
      • Submit Proposal
      • Current RFPs
      • Past RFPs
    • Publications
    • TrialShare
    • Strategic Plans
      • Allergy
      • Autoimmune Disease
        • Type 1 Diabetes
      • Transplantation
  • For Patients
    • Allergy & Asthma
    • Autoimmune Disease
    • Transplantation
      • Kidney
      • Liver
    • Type 1 Diabetes
    • Clinical Trial Info
  • TrialShare
  • Contact
    • Contact Us
      • BRI - Seattle Office
      • UCSF - San Francisco Office
    • Media Inquiries
Home

Secondary links

  • Home
  • TrialShare
  • Member Portal
  • About Us
    • About Us
    • Mission & Values
    • Leadership
    • News
    • Careers
    • Partnerships
    • Support
    • Achievements
  • For Researchers
    • Clinical Trials
    • Core Facilities
    • Lab Protocols
    • Policies
    • Proposals
    • Publications
    • TrialShare
    • Strategic Plans
  • For Patients
    • Allergy & Asthma
    • Autoimmune Disease
    • Transplantation
    • Type 1 Diabetes
    • Clinical Trial Info
  • TrialShare
  • Contact
    • Contact Us
    • Media Inquiries

Primary links (clinical trials)

  • About Us
    • About Us
    • Mission & Values
    • Leadership
    • News
    • Careers
    • Partnerships
    • Support
    • Achievements
  • For Researchers
    • Clinical Trials
      • Allergy & Asthma
      • Autoimmune Disease
      • Transplantation
      • Type 1 Diabetes
    • Core Facilities
    • Lab Protocols
      • ITN Protocols
      • T1D Preclinical Consortium
    • Policies
      • Publications Policy
    • Proposals
      • Submit Proposal
      • Current RFPs
      • Past RFPs
    • Publications
    • TrialShare
    • Strategic Plans
      • Allergy
      • Autoimmune Disease
      • Transplantation
  • For Patients
    • Allergy & Asthma
    • Autoimmune Disease
    • Transplantation
      • Kidney
      • Liver
    • Type 1 Diabetes
    • Clinical Trial Info
  • TrialShare
  • Contact
    • Contact Us
      • BRI - Seattle Office
      • UCSF - San Francisco Office
    • Media Inquiries

A Phase I Study: Safety of RG2077 (CTLA4-IgG4m) in Patients With Relapsing-Remitting Multiple Sclerosis

Principal Investigator

Samia Khoury | Brigham & Women's Hospital | Boston, MA

Locations

Boston, MA

Study Code

ITN006AI

Study Status

Completed

Abstract

Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) initiated by autoreactive CD4+ T cell recognizing and responding to myelin antigens. Our understanding of the immunopathogenesis of MS implicates T cell activation as an important step in the pathogenesis of this autoimmune disease. In experimental autoimmune encephalomyelitis (EAE), the animal model of MS, treatment of animals with CTLA4Ig, a fusion protein that binds and blocks B7 interaction with CD28, suppresses EAE.

We also found that expression of CD28 in the CNS of mice undergoing EAE correlated with disease activity. More importantly, B7 molecules are expressed in plaques from MS brain. Initial studies in humans with CTLA4Ig for the treatment of psoriasis showed that this treatment could safely be administered to patients and appeared to be efficacious.

Our hypothesis is that treatment with CTLA4Ig will arrest the disease if administered early in the course of MS and provides a novel conceptual approach to treat MS with the intent to abort the disease. Our primary objective in this study is to evaluate the safety and immunologic effects of CTLA4Ig therapy in MS. The study will include 3 dose groups (4 patients each) starting with an induction therapy of 3 daily doses followed by 2 monthly treatments of CTLA4Ig with a total duration of study of 4 months. This phase 1 study is not designed to test efficacy but only safety and immunologic responses in treated patients. MRI measures of disease activity (T2 lesion volume, number of gadolinium (GD) enhancing lesions and progression of atrophy) will also serve as safety measures and may provide hints for efficacy information to help design Phase II studies. This clinical study will be accompanied by extensive immunologic studies in order to understand the immunomodulatory functions of CTLA4Ig in MS patients. The immunologic studies will focus on 4 areas of investigation: 1) to look for change in activation state of I cells before and after treatment, 2) to investigate the effect of treatment on markers of inflammation that have been associated with disease activity in MS, 3) to investigate the effect of treatment on the precursor frequency of myelin reactive cells and 4) to investigate the effect of treatment on immune function in vivo.

[Clinicaltrials.gov]

Principal Investigator

Samia Khoury | Brigham & Women's Hospital | Boston, MA

Locations

Boston, MA

Articles

Viglietta V, Bourcier K, Buckle GJ, Healy B, Weiner HL, Hafler DA, Egorova S, Guttmann CRG, Rusche JR, Khoury SJ. (2008) CTLA4Ig treatment in patients with multiple sclerosis: an open-label, phase 1 clinical trial. Neurology, 71 (12), 917-24. DOI: 10.1212/01.wnl.0000325915.00112.61 PMID: 18794494 [PubMed] [Reprint]

The Immune Tolerance Network and is sponsored by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

National Institute of Allergy and Infectious Diseases

Footer

  • Home
  • Sponsors
  • Careers
  • Contact
  • Search

© 2021 Immune Tolerance Network

  • Privacy
  • Terms of Use
  • Accessibility